Utilising organs from hepatitis C virus <scp>PCR</scp>‐positive donors in Western Australia-Reference-Cited by-同舟云学术

Utilising organs from hepatitis C virus PCR‐positive donors in Western Australia

Published:2024-03-07 Issue:4 Volume:54 Page:678-681
ISSN:1444-0903
Container-title:Internal Medicine Journal
language:en
Short-container-title:Internal Medicine Journal

Author:

Boan Peter¹²^ORCID,Jamboti Jagadish³⁴⁵,Musk Michael⁶,Lavender Melanie⁶,Wrobel Jeremy P.⁶⁷,Lee Felicity⁸,Shah Amit⁸,Pereira Lynette A.¹²⁹,Robinson J. Owen¹²⁹,Irish Ashley³

Affiliation:

1. Department of Infectious Diseases Fiona Stanley Hospital Perth Western Australia Australia

2. Department of Microbiology Fiona Stanley Hospital, PathWest Laboratory Medicine Western Australia Perth Western Australia Australia

3. Department of Nephrology Fiona Stanley Hospital Perth Western Australia Australia

4. School of Medicine University of Western Australia Perth Western Australia Australia

5. School of Medicine Curtin University Perth Western Australia Australia

6. Advanced Lung Disease Unit Fiona Stanley Hospital Perth Western Australia Australia

7. Department of Medicine University of Notre Dame Australia Perth Western Australia Australia

8. Advanced Heart Failure and Cardiac Transplant Service Fiona Stanley Hospital Perth Western Australia Australia

9. Department of Infectious Disease Royal Perth Hospital Perth Western Australia Australia

Abstract

AbstractWe transplanted six solid organs from three hepatitis C virus (HCV) polymerase chain reaction (PCR)‐positive donors during 2018–2023. Recipients were treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 4–12 weeks, with all six achieving sustained virological response without significant adverse events. As occurs in other jurisdictions, solid organ transplants from HCR PCR‐positive donors can be safely utilised in Australia.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imj.16345

Reference14 articles.

1. The Use of Hepatitis C Virus–Positive Organs in Hepatitis C Virus–Negative Recipients

2. Five-Year Allograft Survival for Recipients of Kidney Transplants From Hepatitis C Virus Infected vs Uninfected Deceased Donors in the Direct-Acting Antiviral Therapy Era

3. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients

4. The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States

5. Ultra‐short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients